Kidney Cancer Therapy Comprehensive Study by Drug Type (Branded, Generics), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End Use (Hospitals & Clinics, Diagnostic Centers, Ambulatory Surgical Centres, Research & Development Centres, Others), Cancer Type (Clear cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Urothelial carcinoma /Transitional cell carcinoma, Other (Wilms tumor), By Pharmacological Class: (Angiogenesis Inhibitors, MTOR Inhibitors, Cytokines, Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)), Therapy Type (Targeted Therapy, Immunotherapy, Chemotherapy, Radiation Therapy) Players and Region - Global Market Outlook to 2028

Kidney Cancer Therapy Market by XX Submarkets | Forecast Years 2023-2028  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Kidney Cancer Therapy
Kidney cancer, also known as renal cancer, is a group of cancers that starts in the kidney. Kidney cancer treatment depends on the stage and grade of the tumor, as well as your age and overall health. Options include surgery, ablation, radiation therapy, targeted drug therapy, immunotherapy and sometimes chemotherapy. Growing consumption of alcohol, tobacco, and both. And The rise in the incidence of renal cancer is the driver of the market growth.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


The market is highly competitive with a few players occupying the major share. The key players are highly focused on developing and innovating new strategies and product developments to maintain their market position and customer base. The companies are also planning strategic activities like partnerships, collaboration, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (United States), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (United States), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (United States) and Merck & Co., Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Allergan (Ireland), AstraZeneca (United Kingdom), AbbVie Inc. (United States), Johnson & Johnson Private Limited (United States), Cipla Inc. (United States) and Fresenius Kabi AG (Germany).

Segmentation Overview
AMA Research has segmented the market of Global Kidney Cancer Therapy market by and Region.



On the basis of geography, the market of Kidney Cancer Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Type, the sub-segment i.e. Branded will boost the Kidney Cancer Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Kidney Cancer Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End Use, the sub-segment i.e. Hospitals & Clinics will boost the Kidney Cancer Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Cancer Type, the sub-segment i.e. Clear cell Renal Cell Carcinoma will boost the Kidney Cancer Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by By Pharmacological Class:, the sub-segment i.e. Angiogenesis Inhibitors will boost the Kidney Cancer Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapy Type , the sub-segment i.e. Targeted Therapy will boost the Kidney Cancer Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Advancements in Drug delivery

Market Growth Drivers:
Growing consumption of alcohol, tobacco, and both. and The rise in the incidence of renal cancer

Restraints:
The growing use of biologics and targeted treatments limits the market for kidney cancer drugs.

Opportunities:
Treatment with chemotherapy is costly.

Market Leaders and their expansionary development strategies

In October 2022, a new study from a national insurerís claims dataset journal of the American college of surgeons suggested the more cost-effective FIT than mt-DNA testing for the non-invasive detection of colorectal without compromising the quality of care.


Key Target Audience
pharmaceutical companies, Biotechnological institutes, Government and private laboratories, Research and Development (R&D) companies, Medical research laboratories, Market research and consulting service providers, Government Agencies, End User Industry and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Drug Type
  • Branded
  • Generics

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By End Use
  • Hospitals & Clinics
  • Diagnostic Centers
  • Ambulatory Surgical Centres
  • Research & Development Centres
  • Others

By Cancer Type
  • Clear cell Renal Cell Carcinoma
  • Papillary Renal Cell Carcinoma
  • Chromophobe Renal Cell Carcinoma
  • Urothelial carcinoma /Transitional cell carcinoma
  • Other (Wilms tumor

By By Pharmacological Class:
  • Angiogenesis Inhibitors
  • MTOR Inhibitors
  • Cytokines
  • Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)

By Therapy Type
  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy
  • Radiation Therapy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing consumption of alcohol, tobacco, and both.
      • 3.2.2. The rise in the incidence of renal cancer
    • 3.3. Market Trends
      • 3.3.1. Advancements in Drug delivery
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Kidney Cancer Therapy, by Drug Type, Distribution Channel, End Use, Cancer Type, By Pharmacological Class:, Therapy Type and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Kidney Cancer Therapy (Value)
      • 5.2.1. Global Kidney Cancer Therapy by: Drug Type (Value)
        • 5.2.1.1. Branded
        • 5.2.1.2. Generics
      • 5.2.2. Global Kidney Cancer Therapy by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Online Pharmacies
      • 5.2.3. Global Kidney Cancer Therapy by: End Use (Value)
        • 5.2.3.1. Hospitals & Clinics
        • 5.2.3.2. Diagnostic Centers
        • 5.2.3.3. Ambulatory Surgical Centres
        • 5.2.3.4. Research & Development Centres
        • 5.2.3.5. Others
      • 5.2.4. Global Kidney Cancer Therapy by: Cancer Type (Value)
        • 5.2.4.1. Clear cell Renal Cell Carcinoma
        • 5.2.4.2. Papillary Renal Cell Carcinoma
        • 5.2.4.3. Chromophobe Renal Cell Carcinoma
        • 5.2.4.4. Urothelial carcinoma /Transitional cell carcinoma
        • 5.2.4.5. Other (Wilms tumor
      • 5.2.5. Global Kidney Cancer Therapy by: By Pharmacological Class: (Value)
        • 5.2.5.1. Angiogenesis Inhibitors
        • 5.2.5.2. MTOR Inhibitors
        • 5.2.5.3. Cytokines
        • 5.2.5.4. Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
      • 5.2.6. Global Kidney Cancer Therapy Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Kidney Cancer Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Mylan N.V. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceutical Industries Ltd. (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GlaxoSmithKline plc (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bayer AG (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lilly and Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Merck & Co., Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Kidney Cancer Therapy Sale, by Drug Type, Distribution Channel, End Use, Cancer Type, By Pharmacological Class:, Therapy Type and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Kidney Cancer Therapy (Value)
      • 7.2.1. Global Kidney Cancer Therapy by: Drug Type (Value)
        • 7.2.1.1. Branded
        • 7.2.1.2. Generics
      • 7.2.2. Global Kidney Cancer Therapy by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Online Pharmacies
      • 7.2.3. Global Kidney Cancer Therapy by: End Use (Value)
        • 7.2.3.1. Hospitals & Clinics
        • 7.2.3.2. Diagnostic Centers
        • 7.2.3.3. Ambulatory Surgical Centres
        • 7.2.3.4. Research & Development Centres
        • 7.2.3.5. Others
      • 7.2.4. Global Kidney Cancer Therapy by: Cancer Type (Value)
        • 7.2.4.1. Clear cell Renal Cell Carcinoma
        • 7.2.4.2. Papillary Renal Cell Carcinoma
        • 7.2.4.3. Chromophobe Renal Cell Carcinoma
        • 7.2.4.4. Urothelial carcinoma /Transitional cell carcinoma
        • 7.2.4.5. Other (Wilms tumor
      • 7.2.5. Global Kidney Cancer Therapy by: By Pharmacological Class: (Value)
        • 7.2.5.1. Angiogenesis Inhibitors
        • 7.2.5.2. MTOR Inhibitors
        • 7.2.5.3. Cytokines
        • 7.2.5.4. Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
      • 7.2.6. Global Kidney Cancer Therapy Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Kidney Cancer Therapy: by Drug Type(USD Million)
  • Table 2. Kidney Cancer Therapy Branded , by Region USD Million (2017-2022)
  • Table 3. Kidney Cancer Therapy Generics , by Region USD Million (2017-2022)
  • Table 4. Kidney Cancer Therapy: by Distribution Channel(USD Million)
  • Table 5. Kidney Cancer Therapy Hospital Pharmacies , by Region USD Million (2017-2022)
  • Table 6. Kidney Cancer Therapy Retail Pharmacies , by Region USD Million (2017-2022)
  • Table 7. Kidney Cancer Therapy Online Pharmacies , by Region USD Million (2017-2022)
  • Table 8. Kidney Cancer Therapy: by End Use(USD Million)
  • Table 9. Kidney Cancer Therapy Hospitals & Clinics , by Region USD Million (2017-2022)
  • Table 10. Kidney Cancer Therapy Diagnostic Centers , by Region USD Million (2017-2022)
  • Table 11. Kidney Cancer Therapy Ambulatory Surgical Centres , by Region USD Million (2017-2022)
  • Table 12. Kidney Cancer Therapy Research & Development Centres , by Region USD Million (2017-2022)
  • Table 13. Kidney Cancer Therapy Others , by Region USD Million (2017-2022)
  • Table 14. Kidney Cancer Therapy: by Cancer Type(USD Million)
  • Table 15. Kidney Cancer Therapy Clear cell Renal Cell Carcinoma , by Region USD Million (2017-2022)
  • Table 16. Kidney Cancer Therapy Papillary Renal Cell Carcinoma , by Region USD Million (2017-2022)
  • Table 17. Kidney Cancer Therapy Chromophobe Renal Cell Carcinoma , by Region USD Million (2017-2022)
  • Table 18. Kidney Cancer Therapy Urothelial carcinoma /Transitional cell carcinoma , by Region USD Million (2017-2022)
  • Table 19. Kidney Cancer Therapy Other (Wilms tumor , by Region USD Million (2017-2022)
  • Table 20. Kidney Cancer Therapy: by By Pharmacological Class:(USD Million)
  • Table 21. Kidney Cancer Therapy Angiogenesis Inhibitors , by Region USD Million (2017-2022)
  • Table 22. Kidney Cancer Therapy MTOR Inhibitors , by Region USD Million (2017-2022)
  • Table 23. Kidney Cancer Therapy Cytokines , by Region USD Million (2017-2022)
  • Table 24. Kidney Cancer Therapy Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others) , by Region USD Million (2017-2022)
  • Table 25. South America Kidney Cancer Therapy, by Country USD Million (2017-2022)
  • Table 26. South America Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 27. South America Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 28. South America Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 29. South America Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 30. South America Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 31. South America Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 32. Brazil Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 33. Brazil Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 34. Brazil Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 35. Brazil Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 36. Brazil Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 37. Brazil Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 38. Argentina Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 39. Argentina Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 40. Argentina Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 41. Argentina Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 42. Argentina Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 43. Argentina Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 44. Rest of South America Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 45. Rest of South America Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 46. Rest of South America Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 47. Rest of South America Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 48. Rest of South America Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 49. Rest of South America Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 50. Asia Pacific Kidney Cancer Therapy, by Country USD Million (2017-2022)
  • Table 51. Asia Pacific Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 52. Asia Pacific Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 53. Asia Pacific Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 54. Asia Pacific Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 55. Asia Pacific Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 56. Asia Pacific Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 57. China Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 58. China Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 59. China Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 60. China Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 61. China Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 62. China Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 63. Japan Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 64. Japan Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 65. Japan Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 66. Japan Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 67. Japan Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 68. Japan Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 69. India Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 70. India Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 71. India Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 72. India Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 73. India Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 74. India Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 75. South Korea Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 76. South Korea Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 77. South Korea Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 78. South Korea Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 79. South Korea Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 80. South Korea Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 81. Taiwan Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 82. Taiwan Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 83. Taiwan Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 84. Taiwan Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 85. Taiwan Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 86. Taiwan Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 87. Australia Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 88. Australia Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 89. Australia Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 90. Australia Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 91. Australia Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 92. Australia Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 93. Rest of Asia-Pacific Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 94. Rest of Asia-Pacific Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 95. Rest of Asia-Pacific Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 96. Rest of Asia-Pacific Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 97. Rest of Asia-Pacific Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 98. Rest of Asia-Pacific Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 99. Europe Kidney Cancer Therapy, by Country USD Million (2017-2022)
  • Table 100. Europe Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 101. Europe Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 102. Europe Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 103. Europe Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 104. Europe Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 105. Europe Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 106. Germany Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 107. Germany Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 108. Germany Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 109. Germany Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 110. Germany Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 111. Germany Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 112. France Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 113. France Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 114. France Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 115. France Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 116. France Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 117. France Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 118. Italy Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 119. Italy Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 120. Italy Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 121. Italy Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 122. Italy Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 123. Italy Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 124. United Kingdom Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 125. United Kingdom Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 126. United Kingdom Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 127. United Kingdom Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 128. United Kingdom Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 129. United Kingdom Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 130. Netherlands Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 131. Netherlands Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 132. Netherlands Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 133. Netherlands Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 134. Netherlands Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 135. Netherlands Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 136. Rest of Europe Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 137. Rest of Europe Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 138. Rest of Europe Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 139. Rest of Europe Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 140. Rest of Europe Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 141. Rest of Europe Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 142. MEA Kidney Cancer Therapy, by Country USD Million (2017-2022)
  • Table 143. MEA Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 144. MEA Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 145. MEA Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 146. MEA Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 147. MEA Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 148. MEA Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 149. Middle East Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 150. Middle East Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 151. Middle East Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 152. Middle East Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 153. Middle East Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 154. Middle East Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 155. Africa Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 156. Africa Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 157. Africa Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 158. Africa Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 159. Africa Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 160. Africa Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 161. North America Kidney Cancer Therapy, by Country USD Million (2017-2022)
  • Table 162. North America Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 163. North America Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 164. North America Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 165. North America Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 166. North America Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 167. North America Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 168. United States Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 169. United States Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 170. United States Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 171. United States Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 172. United States Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 173. United States Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 174. Canada Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 175. Canada Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 176. Canada Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 177. Canada Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 178. Canada Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 179. Canada Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 180. Mexico Kidney Cancer Therapy, by Drug Type USD Million (2017-2022)
  • Table 181. Mexico Kidney Cancer Therapy, by Distribution Channel USD Million (2017-2022)
  • Table 182. Mexico Kidney Cancer Therapy, by End Use USD Million (2017-2022)
  • Table 183. Mexico Kidney Cancer Therapy, by Cancer Type USD Million (2017-2022)
  • Table 184. Mexico Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2017-2022)
  • Table 185. Mexico Kidney Cancer Therapy, by Therapy Type USD Million (2017-2022)
  • Table 186. Company Basic Information, Sales Area and Its Competitors
  • Table 187. Company Basic Information, Sales Area and Its Competitors
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Kidney Cancer Therapy: by Drug Type(USD Million)
  • Table 197. Kidney Cancer Therapy Branded , by Region USD Million (2023-2028)
  • Table 198. Kidney Cancer Therapy Generics , by Region USD Million (2023-2028)
  • Table 199. Kidney Cancer Therapy: by Distribution Channel(USD Million)
  • Table 200. Kidney Cancer Therapy Hospital Pharmacies , by Region USD Million (2023-2028)
  • Table 201. Kidney Cancer Therapy Retail Pharmacies , by Region USD Million (2023-2028)
  • Table 202. Kidney Cancer Therapy Online Pharmacies , by Region USD Million (2023-2028)
  • Table 203. Kidney Cancer Therapy: by End Use(USD Million)
  • Table 204. Kidney Cancer Therapy Hospitals & Clinics , by Region USD Million (2023-2028)
  • Table 205. Kidney Cancer Therapy Diagnostic Centers , by Region USD Million (2023-2028)
  • Table 206. Kidney Cancer Therapy Ambulatory Surgical Centres , by Region USD Million (2023-2028)
  • Table 207. Kidney Cancer Therapy Research & Development Centres , by Region USD Million (2023-2028)
  • Table 208. Kidney Cancer Therapy Others , by Region USD Million (2023-2028)
  • Table 209. Kidney Cancer Therapy: by Cancer Type(USD Million)
  • Table 210. Kidney Cancer Therapy Clear cell Renal Cell Carcinoma , by Region USD Million (2023-2028)
  • Table 211. Kidney Cancer Therapy Papillary Renal Cell Carcinoma , by Region USD Million (2023-2028)
  • Table 212. Kidney Cancer Therapy Chromophobe Renal Cell Carcinoma , by Region USD Million (2023-2028)
  • Table 213. Kidney Cancer Therapy Urothelial carcinoma /Transitional cell carcinoma , by Region USD Million (2023-2028)
  • Table 214. Kidney Cancer Therapy Other (Wilms tumor , by Region USD Million (2023-2028)
  • Table 215. Kidney Cancer Therapy: by By Pharmacological Class:(USD Million)
  • Table 216. Kidney Cancer Therapy Angiogenesis Inhibitors , by Region USD Million (2023-2028)
  • Table 217. Kidney Cancer Therapy MTOR Inhibitors , by Region USD Million (2023-2028)
  • Table 218. Kidney Cancer Therapy Cytokines , by Region USD Million (2023-2028)
  • Table 219. Kidney Cancer Therapy Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others) , by Region USD Million (2023-2028)
  • Table 220. South America Kidney Cancer Therapy, by Country USD Million (2023-2028)
  • Table 221. South America Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 222. South America Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 223. South America Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 224. South America Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 225. South America Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 226. South America Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 227. Brazil Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 228. Brazil Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 229. Brazil Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 230. Brazil Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 231. Brazil Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 232. Brazil Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 233. Argentina Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 234. Argentina Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 235. Argentina Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 236. Argentina Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 237. Argentina Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 238. Argentina Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 239. Rest of South America Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 240. Rest of South America Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 241. Rest of South America Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 242. Rest of South America Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 243. Rest of South America Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 244. Rest of South America Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 245. Asia Pacific Kidney Cancer Therapy, by Country USD Million (2023-2028)
  • Table 246. Asia Pacific Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 247. Asia Pacific Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 248. Asia Pacific Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 249. Asia Pacific Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 250. Asia Pacific Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 251. Asia Pacific Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 252. China Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 253. China Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 254. China Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 255. China Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 256. China Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 257. China Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 258. Japan Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 259. Japan Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 260. Japan Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 261. Japan Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 262. Japan Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 263. Japan Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 264. India Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 265. India Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 266. India Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 267. India Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 268. India Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 269. India Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 270. South Korea Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 271. South Korea Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 272. South Korea Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 273. South Korea Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 274. South Korea Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 275. South Korea Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 276. Taiwan Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 277. Taiwan Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 278. Taiwan Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 279. Taiwan Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 280. Taiwan Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 281. Taiwan Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 282. Australia Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 283. Australia Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 284. Australia Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 285. Australia Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 286. Australia Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 287. Australia Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 288. Rest of Asia-Pacific Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 289. Rest of Asia-Pacific Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 290. Rest of Asia-Pacific Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 291. Rest of Asia-Pacific Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 292. Rest of Asia-Pacific Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 293. Rest of Asia-Pacific Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 294. Europe Kidney Cancer Therapy, by Country USD Million (2023-2028)
  • Table 295. Europe Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 296. Europe Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 297. Europe Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 298. Europe Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 299. Europe Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 300. Europe Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 301. Germany Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 302. Germany Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 303. Germany Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 304. Germany Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 305. Germany Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 306. Germany Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 307. France Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 308. France Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 309. France Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 310. France Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 311. France Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 312. France Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 313. Italy Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 314. Italy Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 315. Italy Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 316. Italy Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 317. Italy Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 318. Italy Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 319. United Kingdom Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 320. United Kingdom Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 321. United Kingdom Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 322. United Kingdom Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 323. United Kingdom Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 324. United Kingdom Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 325. Netherlands Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 326. Netherlands Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 327. Netherlands Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 328. Netherlands Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 329. Netherlands Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 330. Netherlands Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 331. Rest of Europe Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 332. Rest of Europe Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 333. Rest of Europe Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 334. Rest of Europe Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 335. Rest of Europe Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 336. Rest of Europe Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 337. MEA Kidney Cancer Therapy, by Country USD Million (2023-2028)
  • Table 338. MEA Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 339. MEA Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 340. MEA Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 341. MEA Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 342. MEA Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 343. MEA Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 344. Middle East Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 345. Middle East Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 346. Middle East Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 347. Middle East Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 348. Middle East Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 349. Middle East Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 350. Africa Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 351. Africa Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 352. Africa Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 353. Africa Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 354. Africa Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 355. Africa Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 356. North America Kidney Cancer Therapy, by Country USD Million (2023-2028)
  • Table 357. North America Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 358. North America Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 359. North America Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 360. North America Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 361. North America Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 362. North America Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 363. United States Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 364. United States Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 365. United States Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 366. United States Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 367. United States Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 368. United States Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 369. Canada Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 370. Canada Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 371. Canada Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 372. Canada Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 373. Canada Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 374. Canada Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 375. Mexico Kidney Cancer Therapy, by Drug Type USD Million (2023-2028)
  • Table 376. Mexico Kidney Cancer Therapy, by Distribution Channel USD Million (2023-2028)
  • Table 377. Mexico Kidney Cancer Therapy, by End Use USD Million (2023-2028)
  • Table 378. Mexico Kidney Cancer Therapy, by Cancer Type USD Million (2023-2028)
  • Table 379. Mexico Kidney Cancer Therapy, by By Pharmacological Class: USD Million (2023-2028)
  • Table 380. Mexico Kidney Cancer Therapy, by Therapy Type USD Million (2023-2028)
  • Table 381. Research Programs/Design for This Report
  • Table 382. Key Data Information from Secondary Sources
  • Table 383. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Kidney Cancer Therapy: by Drug Type USD Million (2017-2022)
  • Figure 5. Global Kidney Cancer Therapy: by Distribution Channel USD Million (2017-2022)
  • Figure 6. Global Kidney Cancer Therapy: by End Use USD Million (2017-2022)
  • Figure 7. Global Kidney Cancer Therapy: by Cancer Type USD Million (2017-2022)
  • Figure 8. Global Kidney Cancer Therapy: by By Pharmacological Class: USD Million (2017-2022)
  • Figure 9. South America Kidney Cancer Therapy Share (%), by Country
  • Figure 10. Asia Pacific Kidney Cancer Therapy Share (%), by Country
  • Figure 11. Europe Kidney Cancer Therapy Share (%), by Country
  • Figure 12. MEA Kidney Cancer Therapy Share (%), by Country
  • Figure 13. North America Kidney Cancer Therapy Share (%), by Country
  • Figure 14. Global Kidney Cancer Therapy share by Players 2022 (%)
  • Figure 15. Global Kidney Cancer Therapy share by Players (Top 3) 2022(%)
  • Figure 16. Global Kidney Cancer Therapy share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2022
  • Figure 20. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Mylan N.V. (United States) Revenue: by Geography 2022
  • Figure 22. Teva Pharmaceutical Industries Ltd. (Ireland) Revenue, Net Income and Gross profit
  • Figure 23. Teva Pharmaceutical Industries Ltd. (Ireland) Revenue: by Geography 2022
  • Figure 24. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 25. Sanofi (France) Revenue: by Geography 2022
  • Figure 26. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 28. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2022
  • Figure 30. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 32. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 33. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 34. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 35. Eli Lilly and Company (United States) Revenue: by Geography 2022
  • Figure 36. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Merck & Co., Inc. (United States) Revenue: by Geography 2022
  • Figure 38. Global Kidney Cancer Therapy: by Drug Type USD Million (2023-2028)
  • Figure 39. Global Kidney Cancer Therapy: by Distribution Channel USD Million (2023-2028)
  • Figure 40. Global Kidney Cancer Therapy: by End Use USD Million (2023-2028)
  • Figure 41. Global Kidney Cancer Therapy: by Cancer Type USD Million (2023-2028)
  • Figure 42. Global Kidney Cancer Therapy: by By Pharmacological Class: USD Million (2023-2028)
  • Figure 43. South America Kidney Cancer Therapy Share (%), by Country
  • Figure 44. Asia Pacific Kidney Cancer Therapy Share (%), by Country
  • Figure 45. Europe Kidney Cancer Therapy Share (%), by Country
  • Figure 46. MEA Kidney Cancer Therapy Share (%), by Country
  • Figure 47. North America Kidney Cancer Therapy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (United States)
  • Teva Pharmaceutical Industries Ltd. (Ireland)
  • Sanofi (France)
  • Pfizer Inc. (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Novartis AG (Switzerland)
  • Bayer AG (Germany)
  • Eli Lilly and Company (United States)
  • Merck & Co., Inc. (United States)
Additional players considered in the study are as follows:
Allergan (Ireland) , AstraZeneca (United Kingdom) , AbbVie Inc. (United States) , Johnson & Johnson Private Limited (United States) , Cipla Inc. (United States) , Fresenius Kabi AG (Germany)
Select User Access Type

Key Highlights of Report


Apr 2023 201 Pages 86 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (United States), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (United States), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (United States) and Merck & Co., Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Advancements in Drug delivery" is seen as one of major influencing trends for Kidney Cancer Therapy Market during projected period 2022-2028.
The Kidney Cancer Therapy market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Kidney Cancer Therapy Market Report?